Greenwich LifeSciences, Inc. (GLSI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Building 14
Stafford, TX 77477
United States of America (the)
Phone
832 819 3232
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director | 1.1M | 1964 |
| Eric Rothe | Founder & Independent Director | 65,636 | 1975 |
| Christine T. Fischette | Vice President of Business Development | 0 | 1951 |
| Frank Joseph Daugherty | Chief Medical Officer & Director | 0 | 1951 |
| Jaye L. Thompson | Vice President Clinical & Regulatory Affairs | 0 | 1966 |
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.